Biotech · Public company · New York, NY, US
Nuvation Bio Inc.
Ticker NUVB · SEC CIK 0001811063
Track this companyFree. Adds Nuvation Bio Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials105 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline14
- safusidenibPhase 3 · GliomaClinicalTrials.gov · fetched Nov 12, 2026
- TaletrectinibPhase 3 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- EnzalutamidePhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 2 · Advanced Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- NUV-1511Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- NUV-422Phase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- NUV-422Phase 2 · Advanced Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- SafusidenibPhase 2 · Grade 2 IDH1-mutant GliomaClinicalTrials.gov · fetched Nov 12, 2026
- TaletrectinibPhase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- DS6051bPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- EnzalutamidePhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- NUV-422Phase 1 · GliomaClinicalTrials.gov · fetched Nov 12, 2026
- NUV-868Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- OlaparibPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseasePHASE2 · RECRUITING · started Mar 1, 2027ClinicalTrials.gov NCT07703436 · fetched Nov 12, 2026
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)PHASE3 · RECRUITING · started Aug 21, 2025ClinicalTrials.gov NCT07154706 · fetched Nov 12, 2026
- Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 14, 2024ClinicalTrials.gov NCT06334432 · fetched Nov 12, 2026
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)PHASE3 · RECRUITING · started Jun 5, 2023ClinicalTrials.gov NCT05303519 · fetched Nov 12, 2026
- Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPCPHASE1_PHASE2 · WITHDRAWN · started Sep 1, 2022ClinicalTrials.gov NCT05191017 · fetched Nov 12, 2026
- Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBCPHASE1_PHASE2 · WITHDRAWN · started Sep 1, 2022ClinicalTrials.gov NCT05191004 · fetched Nov 12, 2026
- NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsPHASE1 · TERMINATED · started Mar 29, 2022ClinicalTrials.gov NCT05252390 · fetched Nov 12, 2026
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 1, 2021ClinicalTrials.gov NCT04919811 · fetched Nov 12, 2026
- Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsPHASE1 · TERMINATED · started Dec 8, 2020ClinicalTrials.gov NCT04541225 · fetched Nov 12, 2026
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051bPHASE1 · COMPLETED · started Sep 1, 2014ClinicalTrials.gov NCT02279433 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026